利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.012 秒)

    Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
    2.
    发明申请
    Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases 审中-公开
    在不存在免疫调节剂的情况下外周的屁股的封存作为治疗或预防β-淀粉样蛋白相关疾病的治疗方法

    公开(公告)号：US20050227941A1

    公开(公告)日：2005-10-13

    申请号：US10499125

    申请日：2002-12-17

    申请人： Karen Duff ,  Yasuji Matsuoka

    发明人： Karen Duff ,  Yasuji Matsuoka

    IPC分类号： A61K31/192 ,  A61K31/535 ,  A61K31/655 ,  A61K31/70 ,  A61K31/739 ,  A61K38/17 ,  G01N33/53 ,  G01N33/537 ,  G01N33/543 ,  G01N33/68

    CPC分类号： A61K31/739 ,  A61K31/192 ,  A61K31/535 ,  A61K31/655 ,  A61K31/70 ,  A61K38/1709 ,  G01N33/6896 ,  G01N2800/52

    摘要： The present invention describes a method of administering an Aβ-binding agent or drug which has affinity for amyloid beta (Aβ) in the periphery (blood) and reducing Aβ levels in the brain without the need for the agent or drug to enter the brain itself. The Aβ-binding agents utilized in the methods of the invention are preferably non-immunomodulating agents (e.g., antigenic peptides or antibodies) and bind to Aβ in the periphery, or blood. Such compounds do not significantly cross the blood/brain barrier, and yet they lower amyloid (Aβ) levels in the brain, thereby serving as safer, therapeutic and prophylactic treatments against diseases associated with Aβ in the brain, e.g., Alzheimer's Disease and amyloid angiopathy, as well as against other AD-related amyloidoses.

    摘要翻译： 本发明描述了一种在外周（血液）中对淀粉样蛋白β（Abeta）具有亲和性并降低脑中Abeta水平而不需要药物或药物进入脑本身的Abeta结合剂或药物的方法 。 在本发明的方法中使用的抗原结合剂优选为非免疫调节剂（例如抗原肽或抗体）并且结合外周的Abeta或血液。 这些化合物不会显着穿过血液/脑屏障，但它们降低大脑中的淀粉样蛋白（Abeta）水平，从而对于与脑中的Abeta相关的疾病，例如阿尔茨海默氏病和淀粉样血管病变，作为更安全，治疗和预防性治疗 ，以及与其他AD相关的淀粉样变性。

    TRANSGENIC MICE COMPRISING A GENOMIC HUMAN TAU TRANSGENE
    3.
    发明申请
    TRANSGENIC MICE COMPRISING A GENOMIC HUMAN TAU TRANSGENE 审中-公开
    包含基因组人类转移基因的转基因小鼠

    公开(公告)号：US20070118915A1

    公开(公告)日：2007-05-24

    申请号：US11612698

    申请日：2006-12-19

    申请人： Karen Duff ,  Peter Davies

    发明人： Karen Duff ,  Peter Davies

    IPC分类号： A01K67/027

    CPC分类号： C07K14/4711 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2227/105 ,  A01K2267/0312 ,  C12N15/8509 ,  C12N2517/02 ,  C12N2830/85

    摘要： The invention provides transgenic mice comprising tau transgenes, and methods of preparing and using the transgenic mice. For example, the invention provides a transgenic mouse, the genome of the cells of which stably comprise a DNA molecule which comprises a human genomic DNA sequence comprising a human tau promoter and which DNA sequence encodes human tau.

    摘要翻译： 本发明提供了包含tau转基因的转基因小鼠，以及制备和使用转基因小鼠的方法。 例如，本发明提供了一种转基因小鼠，其细胞的基因组稳定地包含DNA分子，其包含人类基因组DNA序列，其包含人tau启动子，并且DNA序列编码人tau。

    Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
    4.
    发明授权
    Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes 失效
    表达APPK670N，M671L和突变型早老素转基因的转基因小鼠

    公开(公告)号：US5898094A

    公开(公告)日：1999-04-27

    申请号：US903518

    申请日：1997-07-30

    申请人： Karen Duff ,  John Hardy

    发明人： Karen Duff ,  John Hardy

    IPC分类号： A01K67/027 ,  A61K49/00 ,  C07K14/47 ,  C12N15/09 ,  C12N15/85 ,  C12Q1/68 ,  C12N15/00 ,  C12N5/00

    CPC分类号： C12N15/8509 ,  A61K49/0008 ,  C07K14/4711 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0312

    摘要： A method of preparing a transgenic animal model with enhanced, accelerated pathology for Alzheimer's Disease (AD) and the transgenic animal made by the method is disclosed. The method includes producing an F.sub.1 generation by crossing a first and second transgenic parent each carrying a different expressible transgene for differing aspects of the same desired phenotype associated with AD pathology. The offspring of the F.sub.1 generation are then screened and those which carry a transgene from each parental transgenic animal resulting in an enhanced pathology for Alzheimer's Disease are selected. In a preferred embodiment the AD-associated pathology is for amyloid accumulation. In an embodiment a mutant presenilin transgene and a transgene for a mutant amyloid precursor protein are used. In a further embodiment the mutant presenilin transgene is the PS1 M146L mutation and the mutant amyloid precursor protein transgene is the Swedish mutation (APP695 isoform containing a K670N,M671L mutation (APP770 numbering)).

    摘要翻译： 公开了一种制备具有阿尔茨海默氏病（AD）增强，加速病理学和通过该方法制备的转基因动物的转基因动物模型的方法。 该方法包括通过与携带不同可表达转基因的第一和第二转基因亲本杂交产生F1代，用于与AD病理学相关的相同所需表型的不同方面。 然后筛选F1代的后代，选择携带来自每个亲本转基因动物的转基因的后代，导致阿尔茨海默氏病的增强的病理学。 在优选实施方案中，AD相关病理学用于淀粉样蛋白积聚。 在一个实施方案中，使用突变型早老素转基因和用于突变淀粉样蛋白前体蛋白的转基因。 在另一个实施方案中，突变型早老素转基因是PS1 M146L突变，突变淀粉样蛋白前体蛋白转基因是瑞典突变（含有K670N，M671L突变（APP770编号）的APP695同种型）。